About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Terbutaline Concentrations in Blood and Urine | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 4NCT00914797

Terbutaline Concentrations in Blood and Urine

The purpose of this study is to assess the blood and urine concentrations of terbutaline and to evaluate the difference between inhaled and oral terbutaline in order to distinguish treatment with terb...

Lead sponsor: Bispebjerg Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Jimmi Elers½, MD

CONTACT

+45 35313208 [email protected]

Sponsors

Lead Sponsor

Bispebjerg Hospital

Collaborators

Hormone Laboratory, Aker University Hospital, Oslo, Norway

To investigate the serum and urine concentrations of terbutaline and evaluate the difference between inhaled terbutaline (2 mg) and oral terbutaline (10 mg) in order to distinguish doping with terbutaline from anti-asthmatic treatment with terbutaline. To investigate the above mentioned in three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.

Age

18 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Physician-diagnosed asthma with positive reversibility or challenge test.
•Informed consent.
•Age between 18 - 45 years.
•Sex: male.
•Asthma classified as mild to moderate according to GINA guidelines.
•Used beta-2-agonist in minimum 12 months.

Exclusion Criteria

•Smokers or ex-smokers with a smoking history of 10 pack years or more.
•Respiratory tract infections within the last 2 weeks prior to visit 1 and 2.
•Subjects with other chronic diseases than asthma and allergy.
•Allergy towards the study medicine.
•Use of beta-2-agonist 6 days prior to study day.

Related studies

RECRUITINGPhase 2

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · Asthma

Remote Anxiety Management for ICS-resistant Asthma Study

NCT06732141 · Asthma

RECRUITINGPhase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT07245576 · Asthma, COPD

Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

NCT07160868 · Asthma (Diagnosis), OSA - Obstructive Sleep Apnea, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 5, 2009Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment30

Start dateJul 2009

Last updatedJun 5, 2009

Condition

Locations shown

Bispebjerg Hospital, Respiratory Research Unit

København NV

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions